, Volume 52, Supplement 4, pp 3–8 | Cite as

How Do Calcium Channel Blockers Prevent Cardiovascular Events

Are They All Alike?
  • Marc G. Bogaert


The calcium channel blockers (calcium antagonists) have vasodilatory and cardiodepressant effects. These pharmacological properties explain, to a large extent, the antihypertensive, antianginal, and antiarrhythmic effects of these agents. Pharmacological differences between members of this class, e.g. differences in vascular selectivity, are well documented and can be exploited clinically.

The efficacy of calcium channel blockers in the prevention of cardiovascular events may depend on factors other than their vasodilatory and cardiodepressive effects. Much interest, for example, has been shown in their possible antiatherosclerotic effects. It is, however, at present not possible to ascertain how important these and other ancillary effects (such as plaque stabilisation) are for the putative cardioprotective effects of calcium channel blockers. There are, moreover, few in vitro or in vivo (animal or clinical) studies allowing valid comparison of the different calcium channel blockers with regard to these ancillary properties.


Nifedipine Diltiazem Calcium Channel Blocker Calcium Antagonist Cell Vascular Endothelial Growth Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Materson B. Calcium channel blockers. Is it time to split the lump? Am J Hypertens 1995; 8: 325–9.Google Scholar
  2. 2.
    Vanhoutte P, Paoletti R. The WHO classification of calcium channel blockers. Trends Pharmacol Sci 1987; 81: 4–5.CrossRefGoogle Scholar
  3. 3.
    Godfraind T. Cardioselectivity of calcium channel blockers. Cardiovasc Drugs Ther 1994; 8: 353–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Furberg C, Psaty B, Meyer J. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31.PubMedCrossRefGoogle Scholar
  5. 5.
    Poole-Wilson P. 24-Hour protection and control: a new era of calcium antagonists. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: v–vi.CrossRefGoogle Scholar
  6. 6.
    Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Barnett A. FDA committee rules calcium-channel blockers safe. Lancet 1996; 347: 313.CrossRefGoogle Scholar
  8. 8.
    Opie L, Messerli F. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995; 92: 1068–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Dzau V. Pathobiology of atherosclerosis and plaque complications. Am Heart J 1994; 128: 1300–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Nayler WG. Amlodipine. Berlin: Springer-Verlag, 1993.CrossRefGoogle Scholar
  12. 12.
    Waters D, Lespérance J. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am Heart J 1994; 128: 1309–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Lichtlen P, Hugenholtz P, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Waters D, Lespérance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940–53.PubMedCrossRefGoogle Scholar
  15. 15.
    Schroeder J, Gao S-Z, Alderman E, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328: 164–70.PubMedCrossRefGoogle Scholar
  16. 16.
    Levine G, Keaney J, Vita J. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995; 332: 512–21.PubMedCrossRefGoogle Scholar
  17. 17.
    Hillegass W, Ohman E, Leimberger J, et al. Ameta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol 1994; 73: 835–9.PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Marc G. Bogaert
    • 1
  1. 1.Heymans Institute of PharmacologyGent University Medical SchoolGentBelgium

Personalised recommendations